OGT Launches New Panel and Workflow Solutions

OGT, a Sysmex Group company and supplier of clinical and diagnostic genomic solutions, announced the launch of the SureSeq Myeloid Plus panel and OGT Universal Next Generation Sequencing (NGS) Complete Workflow on Oct. 5, 2022. The SureSeq is designed to detect aberration in genes implicated in various myeloid disorders, while the workflow is designed to significantly reduce hands-on-time when working with hematology, inherited, and rare disease panels.

According to a company press release, the new SureSeq panels is able to detect single nucleotide variants (SNVs), insertion–deletion mutations (indels), internal tandem duplications (ITDs), and partial tandem duplications (PTDs) within 49 genes. These genes are associated with myeloid disorders, including acute myeloid leukemia (AML), myeloproliferative neoplasms, and myelodysplastic syndrome, among others.

The product is designed to deliver coverage uniformity for low-frequency variants, even in difficult-to-sequence adenine-thymine/guanine-cytosine (AT/GC)-rich regions and regions covering ITDs and PTDs. According to the release, these are common somatic variants in AML and are often associated with poor prognosis and an aggressive form of the disease.

The NGS Workflow is designed to complement the panel, which is designed to be more amenable to automation. According to the release, the Workflow has been upgraded with improvements in copy number variant interpretation, annotation, visualization, and sample data import and display.

“Thanks to our unmatched expertise in bait design, and through partnering with leading cancer experts, we have developed a powerful tool for myeloid research with a highly efficient workflow,” said Adrian Smith, CEO, OGT, in the release. “This enables clinical researchers to quickly and confidently detect all relevant variants in one simple assay. NGS is a key area of expertise for OGT, and we have exciting plans and possibilities for the future.”

Source: OGT